Semaglutide and tirzepatide are different active ingredients. The labels call semaglutide a GLP-1 receptor agonist, and tirzepatide a GIP receptor and GLP-1 receptor agonist.[1][3] Both are given once weekly by injection in the products below, but the dose amounts, forms and missed-dose rules differ.

This page compares the labels of Ozempic and Wegovy (semaglutide) with Mounjaro and Zepbound (tirzepatide), read on DailyMed on 20 November 2026. It compares label facts only. It does not compare results or side effects and does not say which is better. The prescriber chooses the medicine and the dose.

Side by side

SemaglutideTirzepatide
Brands on this pageOzempic, Wegovy (Novo Nordisk)Mounjaro, Zepbound (Eli Lilly and Company)
Class, as labelledGLP-1 receptor agonistGIP receptor and GLP-1 receptor agonist
Injection scheduleOnce weekly, same day each weekOnce weekly
Doses per injection on the labelsOzempic 0.25 to 2 mg; Wegovy 0.25 to 7.2 mg2.5 to 15 mg (both brands)
Label maximumOzempic 2 mg weekly; Wegovy 7.2 mg weekly (adult weight reduction)15 mg weekly (adults); Mounjaro 10 mg weekly for children 10 and older
Injection formsMulti-dose pens, single-dose pens, single-dose syringesSingle-dose pens and vials, multi-dose vials, KwikPens
Branded vialsNoneSingle-dose (0.5 mL) and multi-dose (4 × 0.6 mL)
TabletsYes (Wegovy, Ozempic and Rybelsus tablets)No
Missed doseOzempic: within 5 days. Wegovy injection: depends on whether the next dose is more or less than 2 days awayWithin 4 days (96 hours), otherwise skip
Changing the weekly dayOzempic: at least 2 days (more than 48 hours) between doses. Wegovy (Medication Guide): last dose 2 or more days beforeAt least 3 days (72 hours) between doses
Half-life (section 12.3)Approximately 1 weekApproximately 5 days (Mounjaro); 5–6 days (Zepbound)
Time to peak after an injection1 to 3 days8 to 72 hours (Zepbound: median 24 hours)
Steady state with weekly dosing4 to 5 weeks (Ozempic)After 4 weeks

Sources: sections 1, 2, 3 and 12.3 of each label.[1][2][3][4]

The milligram numbers are not comparable

The two ingredients are dosed on different scales: the semaglutide injections on these labels go from 0.25 mg to 7.2 mg, the tirzepatide injections from 2.5 mg to 15 mg. None of the four labels gives a way to convert a semaglutide dose into a tirzepatide dose, or back. A change from one to the other is the prescriber’s decision, and the dose that follows is theirs too.

Two labels also say not to combine them with similar products. The Wegovy label says use “with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”[2] The Zepbound label says “Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”[4]

Forms and arithmetic

Semaglutide brand injections come only in pens and prefilled syringes, which are dialled or fixed in mg, so there is no unit arithmetic with them. Tirzepatide brands also come in vials, where the label gives the volume per dose: 0.5 mL for a single-dose vial and 0.6 mL for a multi-dose vial. See Zepbound and Mounjaro vials: mL per dose and how many doses are in a GLP-1 pen.

For a compounded vial of either ingredient, the arithmetic depends on that vial’s own label concentration. The semaglutide calculator and tirzepatide calculator work from it, and the dose volume calculator in label-concentration mode takes a printed mg per mL.

Half-life and missed-dose windows

The labels give semaglutide a longer half-life than tirzepatide, about 1 week against about 5 days. The two are explained, with an illustration of what halving means, on semaglutide half-life and tirzepatide half-life. The missed-dose windows are label rules, not something to work out from the half-life.

By brand

For two brands of the same ingredient, see Ozempic vs Wegovy and Mounjaro vs Zepbound. Each brand also has its own label page: Ozempic, Wegovy, Mounjaro and Zepbound.

Last checked against the labels: 20 November 2026.

Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy and Rybelsus are registered trademarks of Novo Nordisk A/S. Kept is independent and not affiliated with, endorsed by or sponsored by Eli Lilly and Company or Novo Nordisk A/S.